Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q1 FY25 Earnings Presentation
17 slides from Shilpa Medicare's earnings presentation, Aug 8, 2024
Slide 1: Cover letter to stock exchanges
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 08 August, 2024 To To Corporate Relationsh
Slide 2: Shilpa Medicare Ltd Q1FY25 Earnings Presentation
Shilpa Medicare Ltd Q1FY25 Earnings Presentation 8 August 2024
Slide 3: Management Commentary
Management Commentary “ Our strategic focus on profitability-led growth continues to yield positive results. Q1FY25 marks our seventh consecutive quarter of EBITDA and margin improvement. This achievement is a testament to our unwavering commitment to operational excellence and our focus on high-val
Slide 4: Business Updates
Business Updates First generic of Nilotinib in the EU market (EU Mkt Size US$ 453 mn*)– launch expected in Q3 through a Formulation top EU Company Business Participated first time in UNICEF tender for Oncology range and have been awarded one product Launch of Lenvatinib in Saudi market by our
Slide 5: Q1 FY25 - Financial Performance
Q1 FY25 - Financial Performance (INR in Cr.) Q1 FY25 (Consolidated) Revenue Break-up Particulars Biologicals, Others, 10.4 Q1 FY25 Q1 FY24 YoY Q4 FY24 QoQ (INR cr) 15.5 Total 4% 302.0 262.1 15% 294.2 3% Revenue 5% Gross Profit 209.1 173.9 20% 197.1 6% Formulation, 103.8 GP Margin 69% 66% 67% Q1 EBIT
Slide 6: Consolidated Performance - Quarterly
Consolidated Performance - Quarterly (INR in Cr.) Revenues EBITDA and Margins 28% 25% 350 24% 20% 300 315 302 19% 250 289 294 83.0 262 72.6 68.2 62.1 200 49.9 150 100 50 0 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 PBT and Margins PAT and Margins 10% 8% 7% 5% 5% 28.7
Slide 7: API Business – Q1FY25 Highlights
API Business – Q1FY25 Highlights (INR in Cr.) Non- Oncology CDMO Polymer Others Total Oncology 5% 1% 39% 12% 24% 4% 84.6 80.6 72.7 73.3 165.6 172.7 8.3 11.5 2.5 1.9 1.5 1.4 Q1 FY24 Q1 FY25 18% 20% 8% 73% 21% 6% 183.3 172.7 91.5 84.6 71.9 73.3 12.5 11.5 5.0 1.4 2.4 1.9 Q4 FY24 Q1 FY25 6
Slide 8: API – Ongoing Developments
API – Ongoing Developments 1. Three molecules completed validation in Q1 FY25 Methotrexate – part of Oncology portfolio as an import substitute molecule Abiretarone acetate – Oncology Developments Liraglutide – Our 3rd peptide molecule 2. Two Oncology Molecules - Palbociclib & Olaparib, for wh
Slide 9: Filings – API
Filings – API API – DMF Filings 57 46 35 23 22 17 14 12 10 8 USFDA EU/EMEA GCC & ROW MFDS Canada Australia China PMDA Japan Russia NZ New product introduction and increase in geographical coverage replicated with 244 DMF filings with major regulatory authorities 8 As on 30th June 2024
Slide 10: Formulations Business – Q1FY25 Highlights
Formulations Business – Q1FY25 Highlights (INR in Cr.) US Europe ROW Domestic Licensing Total 137% 34% 245% 5% 6% 13% 103.8 53.1 56.4 91.8 24.5 16.2 16.0 10.2 4.3 4.6 5.3 5.0 Q1 FY24 Q1 FY25 66% 12% 65% 7% 66% 7% 103.8 96.6 56.4 29.9 33.9 18.4 16.2 9.7 16.0 10.2 4.7 5.0 Q4 FY24 Q1 FY25 9
Slide 11: Formulations – Ongoing Developments
Formulations – Ongoing Developments Phase III Studies for NAFLD expected to be completed in August 2024 for India and Emerging markets NOR - UDCA Data submission planned for SEC approval and product licence for launch in Q3 FY25 SMLNUD07 EU Scientific Advice planned in Q2 FY26 Transdermal Pa
Slide 12: Filings – Formulations
Filings – Formulations Formulations – Regulatory Filings Pending Approved 27 3 74 501 14 254 2 58 13 247 1 16 US ANDA (SML) US NDA (SML) EU ROW Robust regulatory filings to strengthen the base for growth in the formulation segment 11 As on 30th June 2024
Slide 13: Comprehensive CDMO Development
Comprehensive CDMO Development Unicycive Therapeutics Inc. Long term manufacturing and supply SML is expected to receive (NASDAQ:UNCY) reported positive agreement with SML. significant milestone income spanning results from pivotal clinical trial of over filing, approval and launch of the Oxylanthan
Slide 14: Biosimilars – Ongoing Developments
Biosimilars – Ongoing Developments High concentration Adalimumab injection: Adalimumab Received approval in Morocco Received additional indications approval in India – will help in future growth Aflibercept Batches for Phase III clinical trials are ongoing - to initiate the study in Q3FY25 F
Slide 15: Financials
Financials Innovating for affordable healthcare
Slide 16: Profit & Loss Consolidated
Profit & Loss Consolidated Particulars (INR cr) Q1 FY25 Q1 FY24 YoY Q4 FY24 QoQ Revenues 302.0 262.1 15% 294.2 3% Gross Profit 209.1 173.9 20% 197.1 6% Gross Margin % 69% 66% 300 bps 67% 200 bps Employee Cost 72.1 72.9 -1% 66.5 8% Other Expenses 54.0 51.2 5% 58.1 -7% EBITDA 83.0 49.9 66% 72.6 14% EB
Slide 17: Thank You
Thank You Shilpa Medicare: Ernst & Young IR : Dilip Kankani Runjhun Jain/ Sneha Salian Contact: +91 8532 238704 Contact: +91 98207 20993 / +91 98194 30437 Email: dilipkankani@vbshilpa.com Email: runjhun.jain1@in.ey.com / sneha2.salian@in.ey.com 16